

Press release

Lund August 30th, 2022

Scandinavian ChemoTech's subsidiary Vetiqure AB signs an exclusive distributor agreement for Turkey with Hasvet Medikal AS

Vetiqure AB has today signed an exclusive distributor agreement with Hasvet Medikal AS "Hasvet", which is the market leader in veterinary medicine in Turkey.

Turkey, with its 84 million inhabitants, is one of Europe's absolute largest markets and thus has a very large potential despite the strained economic situation of the country. There are approximately 4 million cats and 2.5 million dogs in the country.

Hasvet, which is basically a company that was started and is now run by veterinarians, has grown at a rapid pace and is today the major market leader of medical technology in veterinary medicine in the country. Hasvet is also active in several other countries in the Middle East, although this distributor agreement initially only concerns Turkey. According to Hasvet, the establishment of cancer treatments carried out in clinics in Turkey is considerably lower than in north of Europe. This is, however, something that Hasvet has as a goal; to raise awareness of cancer detection and treatment in clinics, as they have done in other areas. The Hasvet group employs almost 300 people, 55 of whom are veterinarians.

"We at Hasvet are happy to start cooperating with Vetiqure AB. Since the first day we were established, selling products and making a profit has always been in the background. Our main goal is to be a cure for animals, our dear friends. We are a company that grows with its collaborators, with help of their innovative products. We hope our cooperation will continue to increase in coming years." - says Murat Güç, Assistant General Manager Hasvet

"The negotiations with Hasvet have been going on for almost 6 months and we are happy that we have now created the conditions to introduce vetIQure™ and TSE to the veterinary market in Turkey. Although we have high hopes for a quick establishment, we must be humble about the time it will actually take as the treatment is new to the Turkish market, but if there is a company with the right capacity and the right skills for a quick and successful establishment, then it Hasvet." - says Mohan Frick, CEO Scandinavian ChemoTech

About Hasvet

Hasvet was founded in 1996 with the aim of importing, selling and reselling services of veterinary medical devices. Over the years, we have never deviated from our focus on animal health. We have always offered innovative and creative products to veterinarians for animal health purposes. *Hasvet's market share on the Turkish veterinary market is, according to Hasvet, 80%.*

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00
ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,
E-mail: certifiedadviser@penser.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-08-2022 08:30 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.